North American metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.6% during the forecast period. Rising incidences of diabetes and obesity is a major factor accelerating market growth. As per the Centers for Disease Control and Prevention (CDC), in the US, 10.5% of the US population, or 34.2 million people of all ages had diabetes. Diabetes is a form of metabolic disorder as it disrupts the functioning of metabolism. Metformin is mainly used for patients with diabetes that reduces plasma insulin concentration in subjects with diabetes and impaired glucose tolerance and reduces the amount of insulin needed for metabolic control in diabetic patients, showing improvement of insulin activity. Additionally, it preserves ?-cell function in type 2 diabetes patients. 

North American metabolic disorder therapeutics market is segmented based on type and disease. Based on type, the market is classified into drug therapy, gene therapy, cellular transplantation, enzyme replacement therapy, and others. Drug therapy is being significantly preferred for the treatment of metabolic disorders. Pioglitazone (Actos) and Metformin (Glucophage) are some common metabolic drugs that are used for the treatment of the metabolic syndrome. The increasing development of new drugs is further expected to drive the demand for drug therapy for metabolic disorders. For instance, in October 2019, the scientists at Yale University developed a time-released version of the drug that particularly targets cells in the liver, which are responsible to mediate several associated metabolic abnormalities linked with Type 2 diabetes and metabolic syndrome. Based on disease, the market is classified into obesity, diabetes, lysosomal storage disease, hypercholesterolemia, and others.

Some prominent players in the market include AbbVie, Inc., Alexion Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly & Co., and AstraZeneca plc. Partnerships and collaborations are one of the vital strategies adopted by market players. For instance, in March 2020, Eli Lilly and Co. declared the global licensing and research partnership with Sitryx, a biopharmaceutical company engaged in the development of therapeutics in immuno-inflammation and immuno-oncology. Under the partnership, the companies will study up to four new preclinical targets that are found by Sitryx that could result in potential new medicines for autoimmune diseases. Lilly will make a $10 million equity investment in Sitryx and Sitryx will get an upfront payment of $50 million.

Research Methodology

The market study of the North American metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. North American Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
2. North American Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers

• Comprehensive research methodology of the North American metabolic disorder therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the North American metabolic disorder therapeutics market.
• Insights about market determinants which are stimulating the North American metabolic disorder therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.